Physician profile
Daniel Lin
NPI 1831477710
$18,305.15
in general payments reported to CMS, 2019-2025
14 companies · $3,508 in 2025
The $3,508 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,783 · 2020: $18.74 · 2021: $1,870 · 2022: $5,430 · 2023: $2,402 · 2024: $294 · 2025: $3,508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,138 · Food and Beverage: $906 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,137.50 |
| Food and Beverage | $905.98 |
| Education | $159.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $12,096.08 | 2019-2023 | Cabometyx |
| Incyte Corporation | $3,100.69 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $2,411.66 | 2020-2025 | Imfinzi, Lynparza |
| Genentech, INC. | $145.64 | 2023 | Lunsumio, Polivy, Venclexta |
| Ipsen Biopharmaceuticals, INC | $140.00 | 2024 | Onivyde |
| Astrazeneca Uk Limited | $134.99 | 2025 | |
| Allergan, INC. | $117.28 | 2019 | |
| Genentech USA, INC. | $92.18 | 2025 | |
| Merck Sharp & Dohme LLC | $19.81 | 2023 | Keytruda |
| Pfizer INC. | $18.93 | 2024 | |
| Teleflex LLC | $15.96 | 2025 | Deknatel |
| Foundation Medicine, INC. | $11.93 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.